INSIGHTS ON CLINICAL TRIAL PARTNERING

• The Rise Of The Site: Empowering Efficient Clinical Study Execution

  Join the Co-CEO of CRIO, as he explores research site challenges and how site-based technologies can reduce administrative burdens, enhance efficiency, and eliminate redundant one-time-use technologies.

• Tech Transfer Strategies For mAb Drug Products In Late-Phase Launch

  Tech transfer is not just a process of replicating manufacturing steps; it is a complex, multidisciplinary effort that ensures process robustness, scalability, regulatory compliance, and supply chain readiness.

• What Is Interactive Response Technology (IRT)?

  Learn how protocol-driven IRT systems support supply management and randomization to help trial teams cut risk and costs.

• How We Used Intelligent Automation to Transform Vendor Selection

  Discover how your small biotech can achieve faster timelines, improved cost control, and more strategic, transparent choices with a platform leveraging intelligent automation.

• RTSM Software Isn't One-Size-Fits-All, Especially For Small Biotechs

  5/13/2026

  Smaller biotech companies often have very different clinical trial needs than large pharmaceutical organizations, and that includes RTSM.

• Can Your Clinical Trial Partners Protect Data At Global Scale?

  6/19/2026

  Clinical trial data crosses borders, systems, and sponsors daily. This presentation unpacks what responsible privacy looks like on a global scale and how privacy by design keeps studies moving safely.

• How Community-Based Research Models Expand Access

  9/9/2025

  As momentum continues to grow in neurology research, how can community-based research models help overcome recruitment and retention challenges in complex areas like Alzheimer's?

• Optimizing Site Activation To Accelerate Clinical Trials

  6/5/2025

  Clinical trial site activation delays are a major bottleneck in drug development, hampering trial timelines and funding flows. To reverse this trend, site-focused solutions are being prioritized.

• PCI Capacity Update July 2025: Small Molecule Drug Product/Finished Dosage Form

  7/29/2025

  Dr. Rebecca Coutts highlights PCI’s high potent oral solid dose (OSD) and oral liquid capabilities, focusing on site expertise, specialized infrastructure, and handling of complex molecules.